Docetaxel for hormone-refractory prostate cancer

The Lancet

Volumn 372, Issue 9648, 2008, Pages 1461-

  Haines, Ian ^a  

^a CABRINI INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; MITOXANTRONE; PREDNISONE;

CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 54149118789     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61616-5     Document Type: Letter

References (5)

1. Damber J., and Aus G. Prostate cancer. Lancet 371 (2008) 1710-1721
2. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
3. Petrylak D.P., Tangen C.M., Hussain M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
4. Berry W., Dakhil S., Modiano M., et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168 (2002) 2439-2443
5. Shih A., and Jackson II K.C. Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21 (2007) 69-76